Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bristol Myers Squibb Company

https://www.bms.com/

Latest From Bristol Myers Squibb Company

Zenas Raises $200m For Bifunctional Antibody In Autoimmune Diseases

Zenas BioPharma plans to have data from four trials – two under way and two starting this summer – for obexelimab, which targets CD19 and FcγRIIb, within about a year and a half.

Financing Immune Disorders

Stock Watch: Core Business Drags As Roche Disappoints And Sanofi Reclassifies

After the volatility of pandemic-related sales, investor and analyst attention turned to pharma’s core businesses. With exclusivity losses weighing on those large components of pharma, Sanofi’s reclassification may bring some unwelcome attention.

Stock Watch Sales & Earnings

Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff

Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.

Market Intelligence Sales & Earnings

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: Japan’s Ono buys US oncology firm; strong growth but supply issues for Lilly; Novo and Lilly make their money work; BMS cuts jobs, costs; and Big Pharma’s support for bioventures.

Commercial M & A
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Abraxis BioScience, Inc.
    • AbVitro, Inc.
    • Acetylon Pharmaceuticals, Inc.
    • Adnexus Therapeutics, Inc.
    • Allied-Bristol Life Sciences, LLC
    • Amira Pharmaceuticals, Inc.
    • Amylin Pharmaceuticals, Inc.
    • Avila Therapeutics, Inc.
    • Bristol-Myers Company
    • Bristol-Myers K.K.
    • Bristol-Myers Squibb
    • Cardioxyl Pharmaceuticals
    • Celgene Corporation
    • Cormorant Pharmaceuticals
    • Delinia, Inc.
    • EngMab AG
    • Flexus Biosciences, Inc.
    • Gloucester Pharmaceuticals, Inc.
    • ißeCa Therapeutics
    • IFM Therapeutics
    • Impact Biomedicines, Inc.
    • Inhibitex, Inc.
    • iPierian Inc.
    • Juno Therapeutics, Inc.
    • Juno Therapeutics GmbH (Stage Cell Therapeutics GmbH)
    • JW Biotechnology (Shanghai) Co., Ltd
    • Kosan
    • Medarex, Inc.
    • Padlock Therapeutics, Inc.
    • Pharmion Corporation
    • Quanticel Pharmaceuticals, Inc.
    • Receptos, Inc.
    • RedoxTherapies, Inc.
    • Turning Point Therapeutics Inc.
    • Westwood-Squibb Pharmaceuticals
    • X-BODY, Inc.
    • ZymoGenetics, Inc.
    • Forbius
    • MyoKardia Inc.
UsernamePublicRestriction

Register